- Completed enrollment of Phase 2 clinical trial of ACH-4471 in PNH as monotherapy - - Interim data and strategic update planned for December 17, 2018 – - September 30, 2018 cash & securities position of $283 million – - Mary Kay Fenton to step down as CFO at year-end 2018 - NEW HAVEN, Conn.
NEW HAVEN, Conn. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt , President and Chief Executive Officer of Achillion, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Tuesday, October 2, 2018 ,
NEW HAVEN, Conn. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Paul Firuta to the position of Executive Vice President and Chief Operating Officer effective immediately. Mr. Firuta, with 27 years of experience successfully
NEW HAVEN, Conn. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt , President and Chief Executive Officer of Achillion, will present at the Baird 2018 Global Healthcare Conference on Thursday, September 6th, 2018 , at 9:05 a.m.
NEW HAVEN, Conn. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Steven Zelenkofske , D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. Dr.
NEW HAVEN, Conn. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Anthony S. Gibney to the position of Executive Vice President and Chief Business Officer, effective immediately. Mr.
- Global phase 2 clinical programs for ACH-4471 continue to expand in PNH and C3G - - Completed dosing phase 1 clinical study of ACH-5228 and initiated phase 1 study of ACH-5548 - - June 30, 2018 cash position $295.8 million - NEW HAVEN, Conn. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Achillion
- Additional clinical compounds expand factor D portfolio opportunities - NEW HAVEN, Conn. , July 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a clinical-stage pharmaceutical company focused on developing small molecule inhibitors of factor D in the complement
NEW HAVEN, Conn. , June 14, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt , President and Chief Executive Officer of Achillion, will present at the 2018 JMP Securities Life Sciences Conference on Thursday, June 21, 2018 , at 9:00 a.m.
- Oral presentation discussing ACH-4471 and interim biomarker data from the ongoing 14-day Phase 2 study in C3G - - Poster presentation detailing in vitro data showing no significant reduction in serum bactericidal activity with factor D inhibition - NEW HAVEN, Conn.